Clinical trials
CMV clinical trials
Below are recruiting cmv clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06226558Recruiting
Long-Term Health of Children with Congenital CMV in NY
This study will follow children born in New York State who were tested for cytomegalovirus (CMV) as newborns. It aims to understand their long-term health and development, whether they were confirmed to have CMV, a false positive, or even a late detection if born early.
Stony Brook, New YorkAges birth–1 year - NCT06243731Recruiting
Maribavir for CMV after transplant in kidney failure
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
Anderlecht, Brussels CapitalAges 18 years+ - NCT06522880Recruiting
CMV transmission and immune tracking study
This study looks at how cytomegalovirus (CMV) spreads among children and staff at daycare centers. It uses a simple saliva test to check for the virus, which can help researchers better understand how to keep people healthy.
Worcester, MassachusettsAges 1 day–3 years - NCT06694428Recruiting
Testing a software tool for CMV blood test results in pregnancy
This trial is testing a computer program that helps doctors interpret blood test results for CMV infection in pregnant women. If you are pregnant and have had a CMV blood test, this study may help doctors better understand your results.
LimogesAges 18 years+ - NCT06812598Recruiting
Extended letermovir to prevent CMV after stem cell transplant
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
Suzhou, JiangsuAges 18 years+ - NCT07014319RecruitingPhase 2
Maribavir for CMV in lymphoma patients on bispecific antibodies
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
SeoulAges 19 years+ - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07670468RecruitingPhase 1/Phase 2
T-cell therapy for resistant viral infections after transplant or cancer treatment
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
SeoulAges 19 years+ - NCT07009548Enrolling by invitationPhase 4
CytoGam for CMV in solid organ transplant recipients
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Pittsburgh, PennsylvaniaAges 18–75 - NCT06577363Recruiting
Maribavir tablets for CMV infection after transplant
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
Tokyo, TokyoAges Any age - NCT06575374RecruitingPhase 2
Letermovir to prevent CMV after CAR T-cell therapy
This trial tests if a drug called letermovir can safely prevent CMV (a common virus) from reactivating after you receive CAR T-cell therapy (Axi-cel). It may help reduce infections and side effects.
Houston, TexasAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+ - NCT05446571RecruitingPhase 3
Letermovir in pregnancy versus valaciclovir for fetal CMV
This trial tests whether letermovir can treat a baby’s early (first-trimester) congenital CMV infection in pregnancy, compared with the standard drug valaciclovir. The goal is to reduce serious effects from CMV while monitoring safety and pregnancy outcomes.
ParisAges 18 years+ - NCT05432778RecruitingPhase 2
Letermovir to prevent CMV in new heart transplant patients
This Phase 2 trial tests whether the medicine letermovir can prevent a common viral infection (CMV) after a new heart transplant. It may help reduce CMV infection or illness in people who are at moderate to high CMV risk.
LjubljanaAges 18–70 - NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT07096453RecruitingPhase 1/Phase 2
CMV prevention in kidney transplant patients switching to belatacept
This trial tests whether an experimental drug (CMVIG) can prevent CMV infection in kidney transplant patients who are switching to or already on belatacept, a newer immunosuppressant. It may help protect those at higher risk for CMV.
Minneapolis, MinnesotaAges 18–70 - NCT02982902RecruitingEarly Phase 1
T cell treatment for stubborn CMV after stem cell transplant
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
Cleveland, OhioAges 3 months+ - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03736707Recruiting
Testing two breathing machines in very preterm babies
This study compares two ways of helping very preterm infants breathe: a special high-frequency ventilation method versus the standard mechanical ventilator. It aims to see which method works better for preterm babies with breathing failure soon after birth.
Chongqing, Chongqing MunicipalityAges 1 minute–1 hour - NCT04013802RecruitingPhase 1
Multivirus T-cell treatment for EBV, CMV, adenovirus, and BK after transplant
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
Houston, TexasAges Any age - NCT04030676Recruiting
Test for CMV reactivation risk during ulcerative colitis flare
This study checks whether a blood test (QuantiFERON-CMV, related to prior CMV infection) can predict if CMV might reactivate during a severe ulcerative colitis flare. It may help doctors spot people at higher risk and potentially guide monitoring and treatment during hospitalization.
LyonAges 18 years+ - NCT04439916Recruiting
Preventing CMV after lung transplant in special donor/recipient pairs
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
Edmonton, AlbertaAges 18 years+ - NCT06058858Recruiting
CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
ParisAges 1–100
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cmv?
- Yes. Clin2 currently lists 60 recruiting cmv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cmv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cmv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.